On Tuesday, Microsoft Corporation (NASDAQ:MSFT)’s shares inclined 2.18% to $43.98.
Microsoft Corp. declared that its board of directors declared a quarterly dividend of $0.36 per share, reflecting a five cent enhance, or 16.1 percent, over the previous quarter’s dividend. The dividend is payable December 10, 2015 to shareholders of record on November 19, 2015. The ex-dividend date will be November 17, 2015.
Microsoft Corporation, a technology company, develops, licenses, and supports software products, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system. Its Computing and Gaming Hardware segment provides Xbox gaming and entertainment consoles and accessories, second-party and third-party video games, and Xbox Live subscriptions; surface devices and accessories; and Microsoft PC accessories. The company’s Phone Hardware segment offers Lumia phones and other non-Lumia phones.
AbbVie Inc (NYSE:ABBV)’s shares gained 0.44% to $59.20.
AbbVie (ABBV), declared that it presented a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on the randomized, multi-center, open-label Phase III RESONATETM-2 (PCYC-1115) trial assessing the use of IMBRUVICA® (ibrutinib) as compared to chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older. AbbVie declared top-line findings from the trial in June 2015 showing that IMBRUVICA improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints counting overall survival (OS) and overall response rate (ORR) in treatment-naive patients with CLL. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
IMBRUVICA is presently approved for the treatment of patients with CLL who have received at least one preceding therapy and CLL patients (counting treatment-naive) who have del 17p, a genetic aberration that occurs when part of chromosome 17, the location of the tumor suppressor gene p53, has been lost or deleted.
The data have been presented for publication in a peer-reviewed journal and presentation at an forthcoming medical conference.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
At the end of Tuesday’s trade, Viacom, Inc. (NASDAQ:VIAB)‘s shares surged 1.39% to $44.42.
Viacom Inc. declared that Philippe Dauman, President and Chief Executive Officer, will take part in a question-and-answer session at the Goldman Sachs Annual Communacopia Conference on Friday, September 18, 2015, at about 9:40 a.m. (ET). A live webcast of Mr. Dauman’s session will be accessible to the general public through a link on the Investor Relations homepage of Viacom’s website, www.viacom.com.
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form video, applications, games, consumer products, social media, and other entertainment content. It operates in two segments, Media Netoperates and Filmed Entertainment. The Media Netoperates segment provides entertainment content and related branded products through about programmed and operated 230 TV channels, counting MTV, VH1, CMT, Logo, BET, CENTRIC, Nickelodeon, Nick Jr., TeenNick, Nicktoons, Nick at Nite, Comedy Central, TV Land, SPIKE, Channel 5, Tr3s, Paramount Channel, and VIVA, in addition to through online, mobile, and apps.
Navient Corp (NASDAQ:NAVI), ended its Tuesday’s trading session with -0.56% loss, and closed at $12.37.
Navient (NAVI), declared that President and CEO Jack Remondi will present at the Deutsche Bank’s 23rd Annual Leveraged Finance Conference in Scottsdale, Ariz., on Tuesday, Sept. 29. The presentation is planned to start at 6:35 p.m. EDT (3:35 p.m. MST). Any written materials or reports shared during the conference will be accessible at navient.com/investors.
Navient Corporation provides financial products and services in the United States. The company operates in four segments: FFELP Loans, Private Education Loans, Business Services, and Other. It provides federal family education loan program (FFELP) loans and servicing for FFELP loan portfolio; and servicing and asset recovery services for loans on behalf of guarantors of FFELP loans, guaranty agencies, higher education institutions, the United States Department of Education, and other federal clients, in addition to states, courts, and municipalities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
